

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 5718-34

First Inventor or Application Identifier: Pramod Mahajan

Title of Invention: POLY ADP-RIBOSE POLYMERASE GENE
AND ITS USES

Express Mail Label No. EM166797628US

ADDRESS TO: ASSISTANT COMMISSIONER FOR PATENTS
BOX PATENT APPLICATION
WASHINGTON, DC 20231

Transmitted herewith for filing in the United States Patent Office is a patent application for:

Inventors: Pramod Mahajan
8029 Brookview Drive
Urbandale, Iowa 50322

Zhuang Zuo
4728 - 80th Place
Urbandale, Iowa 50322

1. ☒ The Filing Fee has been calculated as shown below:
(Submit an original, and a duplicate for fee processing)

	No. Filed	No. Extra	Small Entity		Large Entity	
			Rate	Fee 0	Rate	Fee 760
BASIC FEE				\$0		\$760
TOTAL CLAIMS:	26 - 20 =	6		X 9 = \$0		x 18 = \$108
INDEP CLAIMS:	3 - 3 =	0		X 39 = \$0		x 78 = \$0
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED				+130 = \$		+260 = \$260
*If the difference in Column 1 is less than zero, enter "0" in Column 2.				TOTAL \$		TOTAL \$ 1128

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 16-0605.

- a. ☒ Fees required under 37 CFR 1.16 (National filing fees).
b. ☒ Fees required under 37 CFR 1.17 (National application processing fees).
☒ A check in the amount of \$ 1,128.00 is enclosed.
☐ The above filing fee will be paid along with Applicant(s) Response to the Notice to File Missing Parts.

2. ☒ Specification; Total Pages 30
3. ☐ _____ Sheets of Formal Drawing(s) (35 USC 113)
4. ☒ Declaration and Power of Attorney; [Total Pages 3]
 - a. ☒ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 16 completed)
 - i. ☐ DELETION OF INVENTOR(S) Signed statement
attached deleting inventor(s) named in the prior
application, see 37 CFR 1.63(d)(2) & 1.33(b).
5. ☐ Microfiche Computer Program (Appendix)
6. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s) (including \$40.00 fee)
8. ☐ 37 CFR 3.73(b) Statement (when there is an assignee); ☐ Power of Attorney
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure Statement (IDS)/PTO-1449; _____ Copies of IDS Citations
11. ☐ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
13. ☐ Small Entity Statement(s)

☐ Statement filed in prior application; status still proper and desired.
14. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
Foreign Priority is _____
15. ☐ Other: _____

16. **If a CONTINUING APPLICATION**, check appropriate box and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation in Part (CIP)
 of prior application No: _____; _____

Prior Application Information: Examiner _____

Group/Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. **CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label **000826**

Attention Of: W. Murray Spruill

Signature: _____

Attorney of Record: W. Murray Spruill

Attorney Registration No. 32,943

Tel Raleigh Office (919) 420-2200

Fax Raleigh Office (919) 420-2260

ALSTON & BIRD LLP

P.O. Drawer 34009

Charlotte NC 28234-4009

"Express Mail" mailing label number EM166797628US

Date of Deposit January 26, 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner For Patents, Washington, DC 20231.

Sheree T. Edington

RTA01/2059698v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Mahajan et al.
Appl. No.: To be assigned
Filed: January 26, 1999
For: POLY ADP-RIBOSE POLYMERASE GENE AND ITS USES


**STATEMENT IN SUPPORT OF FILING A
SEQUENCE LISTING UNDER 37 CFR § 1.821(f)**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence listing, submitted concurrently herewith in accordance with 37 CFR § 1.821(c) and (e), are the same.


Respectfully submitted,


W. Murray Spruill
Attorney for Applicant
Registration No. 32, 943

ALSTON & BIRD LLP
Post Office Drawer 34009
Charlotte, NC 28234
Tel Raleigh Office (919) 420-2200
Fax Raleigh Office (919) 420-2260

"Express Mail" Mailing Label Number EM166797628US
Date of Deposit: January 26, 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner of Patents, Washington, DC 20231.


Sheree T. Edington

POLY ADP-RIBOSE POLYMERASE GENE AND ITS USES

CROSS-REFERENCE

This application claims the benefit of U.S. Provisional Application No. 60/072,785, filed January 27, 1998.

5

FIELD OF THE INVENTION

The invention is drawn to the genetic manipulation of plants.

BACKGROUND OF THE INVENTION

10 The physiological and metabolic state of plant cells directly influences the plant response to external stimuli. The plant response to disease includes a host of cellular processes to enable plants to defend themselves from pathogenic agents. These processes apparently form an integrated set of resistance mechanisms that is activated by initial infection and then limits further spread of the invading pathogenic microorganism.

15 The transformation of plants is a complex process. The process involves contacting cells with a DNA to be integrated into the plant cell genome. Generally, genetic transformation of eukaryotic cells is a random event. That is, the foreign DNA is integrated into the genome at random positions. Often several copies, or parts of copies, of the transforming DNA are integrated in a single position, and/or at
20 different positions, resulting in a transformed cell containing multiple copies of the foreign DNA.

Because the metabolic state of the plant cell is instrumental in various processes, it would be beneficial to be able to influence the state of the cells. Accordingly, there is a need for genes and methods for altering the metabolic state of
25 plant cells.

SUMMARY OF THE INVENTION

Compositions and methods for influencing the metabolic state of plant cells are provided. The compositions comprise poly ADP-ribose polymerase genes and fragments thereof, particularly the maize poly ADP-ribose polymerase gene. The genes or antisense constructions of the genes can be used to transform plant cells and alter the metabolic state of the transformed cell.

In this manner, transformed plants can be obtained having altered metabolic states. The invention has implications in enhancing disease resistance in plants and for methods of genetic transformation of plants.

DETAILED DESCRIPTION OF THE INVENTION

Poly ADP-Ribose Polymerase genes and methods for their use are provided. In particular, the amino acid and nucleotide sequences for the maize poly ADP-ribose polymerase (PARP) are provided as SEQ ID NOs. 2 and 1, respectively. Also of interest are portions of the sequences of the invention. The nucleotide and amino acid sequences of the C-terminal domain of the maize poly ADP-ribose polymerase is provided in SEQ ID NOs. 3 and 4, respectively. The nucleotide sequence of the Zinc fingers is provided in SEQ ID NO. 5.

PARP is generally described as a nuclear enzyme found in most eukaryotes. Structure-function studies have shown that animal PARPs may be divided into at least three subdomains. The N-terminal part contains two zinc fingers and has a high affinity for nicked V-shaped DNA. Interaction of PARP with nicked DNA strongly enhances the activity of the catalytic domain, which is very well conserved among PARPs and located in the carboxyl-terminus of the protein. (Ueda *et al.* (1985) *Ann. Rev. Biochem.* 54:73-100; Sdhah *et al.* (1995) *Anal. Biochem.* 227:1-13).

PARP catalyzes both the transfer of ADP-ribose from NAD⁺, mainly to the carboxyl group of a glutamic acid residue on target proteins, and subsequent ADP-ribose polymerization. (Ueda *et al.* (1985) *Ann. Rev. Biochem.* 54:73-100; Sdhah *et al.* (1995) *Anal. Biochem.* 227:1-13)

PARP is generally required in most cases where DNA is cleaved and rejoined, such as in DNA repair, DNA recombination, gene rearrangements and transposition. PARP has been shown to modify PARP itself, histones, high mobility group chromosomal proteins, topoisomerase, endonucleases and DNA polymerases. (Ueda
5 *et al.* (1985) *Ann. Rev. Biochem.* 54:73-100; Sdhah *et al.* (1995) *Anal. Biochem.* 227:1-13)

Initially, the enzyme synthesizes an ester linkage preferentially between the glutamyl(-) or sometimes the C-terminal(-)carboxyl group on the acceptor protein and the 1'-OH of the ribosyl group of ADP-ribose. Subsequently, up to 45-50 ADP
10 units are added via a 2'-1'phosphodiester bond. Branching of the poly (ADP)-ribosyl chains via the 2'-1'phosphodiester linkages is also observed. See, for example, Ueda *et al.* (1985) *Ann. Rev. Biochem.* 54: 73-100; and Shah *et al.* (1995) *Anal. Biochem.* 227:1-13.

Compositions of the invention include isolated nucleic acid molecules
15 encoding the PARP proteins of the invention, as well as fragments and variants thereof. The term "isolated" refers to material, such as a nucleic acid or a protein, which is: (1) substantially or essentially free from components that normally accompany or interact with it as found in its naturally occurring environment. Thus, for a nucleic acid, the sequence is lacking a flanking sequence either 3' or 5' or both.
20 The isolated material optionally comprises material not found with the material in its natural environment; or (2) if the material is in its natural environment, the material has been synthetically (non-naturally) altered by deliberate human intervention to a composition and/or placed at a locus in the cell (e.g., genome or subcellular organelle) not native to a material found in that environment. The alteration to yield the
25 synthetic material can be performed on the material within or removed from its natural state. For example, a naturally occurring nucleic acid becomes an isolated nucleic acid if it is altered, or if it is transcribed from DNA which has been altered, by non-natural, synthetic (i.e., "man-made") methods performed within the cell from which it originates. See, e.g., Compounds and Methods for Site Directed Mutagenesis in
30 Eukaryotic Cells, Kmiec, U.S. Patent No. 5,565,350; *In Vivo* Homologous Sequence

Targeting in Eukaryotic Cells; Zarling *et al.*, PCT/US93/03868. Likewise, a naturally occurring nucleic acid (e.g., a promoter) becomes isolated if it is introduced by non-naturally occurring means to a locus of the genome not native to that nucleic acid.

Nucleic acids which are "isolated" as defined herein, are also referred to as

5 "heterologous" nucleic acids.

As used herein, "localized within the chromosomal region defined by and including" with respect to particular markers includes reference to a contiguous length of a chromosome delimited by and including the stated markers.

As used herein, "marker" includes reference to a locus on a chromosome that
10 serves to identify a unique position on the chromosome. A "polymorphic marker" includes reference to a marker which appears in multiple forms (alleles) such that different forms of the marker, when they are present in a homologous pair, allow transmission of each of the chromosomes in that pair to be followed. A genotype may be defined by use of one or a plurality of markers.

15 As used herein "operably linked" includes reference to a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions,
20 contiguous and in the same reading frame.

The nucleotide sequences of the invention can be used to isolate other homologous sequences in other plant species. Methods are readily available in the art for the hybridization of nucleic acid sequences. Coding sequences from other plants may be isolated according to well known techniques based on their sequence
25 homology to the coding sequences set forth herein. In these techniques all or part of the maize coding sequence is used as a probe which selectively hybridizes to other PARP coding sequences present in a population of cloned genomic DNA fragments or cDNA fragments (i.e. genomic or cDNA libraries) from a chosen organism. For example, the entire maize PARP sequence or portions thereof may be used as probes
30 capable of specifically hybridizing to corresponding coding sequences and messenger

5 RNAs. To achieve specific hybridization under a variety of conditions, such probes include sequences that are unique and are preferably at least about 10 nucleotides in length, and most preferably at least about 20 nucleotides in length. Such probes may be used to amplify the PARP coding sequences of interest from a chosen organism by the well-known process of polymerase chain reaction (PCR). This technique may be used to isolate additional coding sequences from a desired organism or as a diagnostic assay to determine the presence of coding sequences in an organism.

10 Such techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see, e.g., Sambrook *et al.*, *Molecular Cloning*, eds., Cold Spring Harbor Laboratory Press (1989)) and amplification by PCR using oligonucleotide primers corresponding to sequence domains conserved among the amino acid sequences (see, e.g. Innis *et al.*, *PCR Protocols, a Guide to Methods and Applications*, eds., Academic Press (1990)). For example, hybridization of such sequences may be carried out under conditions of reduced stringency, medium
15 stringency or even stringent conditions (e.g., conditions represented by a wash stringency of 35-40% Formamide with 5x Denhardt's solution, 0.5% SDS and 1x SSPE at 37 C; conditions represented by a wash stringency of 40-45% Formamide with 5x Denhardt's solution, 0.5% SDS, and 1x SSPE at 42 C; and conditions represented by a wash stringency of 50% Formamide with 5x Denhardt's solution,
20 0.5% SDS and 1x SSPE at 42 C, respectively), to DNA encoding the PARP genes disclosed herein in a standard hybridization assay. See J. Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual 2d ed.* (1989) Cold Spring Harbor Laboratory. In general, sequences which code for the defense activators and other activator proteins of the invention and hybridize to the sequences disclosed herein will be at least 50%
25 homologous, 70% homologous, and even 85% homologous or more with the disclosed sequence. That is, the sequence similarity of sequences may range, sharing at least about 50%, about 70%, and even about 85% sequence similarity.

The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) "reference sequence", (b)

"comparison window", (c) "sequence identity", (d) "percentage of sequence identity", and (e) "substantial identity".

(a) As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.

(b) As used herein, "comparison window" means includes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches.

Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith *et al.* (1981) *Adv. Appl. Math.* 2:482; by the homology alignment algorithm of Needleman *et al.* (1970) *J. Mol. Biol.* 48:443; by the search for similarity method of Pearson *et al.* (1988) *Proc. Natl. Acad. Sci.* 85:2444; by computerized implementations of these algorithms, including, but not limited to: CLUSTAL in the PC/Gene program by Intelligenetics, Mountain View, California, GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wisconsin, USA; the CLUSTAL program is well described by Higgins *et al.* (1988) *Gene* 73:237-244; Higgins *et al.* (1989) *CABIOS* 5:151-153; Corpet *et al.* (1988) *Nucleic Acids Research* 16:10881-90; Huang *et al.* (1992) *Computer Applications in the Biosciences* 8:155-65, and Person *et al.* (1994) *Methods of Molecular Biology* 24:307-331; preferred computer alignment methods also include the BLASTP, BLASTN, and

BLASTX algorithms. Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-410. Alignment is also often performed by inspection and manual alignment.

(c) As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences includes reference to the residues in the two sequences which are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g. charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences which differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well-known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, *e.g.*, as implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA).

(d) As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched

positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

(e) (i) The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%, more preferably at least 90% and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%. Polypeptides which are "substantially similar" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5 C to about 20 C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent wash conditions are those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 50, 55, or 60 C. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is that the polypeptide which the first nucleic acid encodes is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

(e) (ii) The terms "substantial identity" in the context of peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference

sequence, preferably 80%, more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window.

Preferably, optimal alignment is conducted using the homology alignment algorithm of Needleman *et al.* (1970) *J. Mol. Biol.* 48:443. An indication that two peptide

5 sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution.

Fragments and variants of the disclosed nucleotide sequences and proteins
10 encoded thereby are also encompassed by the present invention. By "fragment" is intended a portion of the nucleotide sequence or a portion of the amino acid sequence and hence protein encoded thereby. Fragments of a nucleotide sequence may encode protein fragments that retain the biological activity of the native protein and hence confer resistance to nematodes. Alternatively, fragments of a nucleotide sequence that
15 are useful as hybridization probes generally do not encode fragment proteins retaining biological activity. Thus, fragments of a nucleotide sequence may range from at least about 20 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the entire nucleotide sequence encoding the proteins of the invention.

By "variants" is intended substantially similar sequences. For nucleotide
20 sequences, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the proteins conferring resistance to nematodes. Generally, nucleotide sequence variants of the invention will have at least 70%, generally, 80%, preferably up to 90% sequence identity to its respective native nucleotide sequence.

By "variant" protein is intended a protein derived from the native protein by
25 deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Such variants may result
30 from, for example, genetic polymorphism or from human manipulation. Methods for

such manipulations are generally known in the art.

The proteins of the invention may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants of the activator proteins can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel *et al.* (1985) *Proc. Natl. Acad. Sci. USA* 82:488-492; Kunkel *et al.* (1987) *Methods in Enzymol.* 154:367-382; U.S. Patent No. 4,873,192; Walker and Gaastra (eds.) *Techniques in Molecular Biology*, MacMillan Publishing Company, NY (1983) and the references cited therein. Thus, the genes and nucleotide sequences of the invention include both the naturally occurring sequences as well as variant and mutant forms. Likewise, the proteins of the invention encompass both naturally occurring proteins as well as variants and modified forms thereof. Such variants will continue to possess the desired PARP activity. Obviously, the mutations that will be made in the DNA encoding the variant must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. See, EP Patent Application Publication No. 75,444.

PARP is present in all higher eukaryotes. Therefore, it is recognized that the nucleotide sequence encoding the PARP may be utilized from any eukaryotic source, including vertebrates, arthropods, mollusks, slime moulds, dinoflagellates, fungi, mammals, chicken, *Xenopus* and insects. See, for example, Heller *et al.* (1995) *J. Biol. Chem.* 270:11178-11180; Schreiber *et al.* (1995) *Proc. Natl. Acad. Sci. USA* 92:4753-4757; Ueda *et al.* (1985) *Ann. Rev. Biochem.* 54:73-100; Brightwell *et al.* (1975) *Biochem. J.* 147:119-129; Kofler *et al.* (1993) *ibid* 293:275-281; Collinge *et al.* (1994) *Mol. Gen. Genet.* 245:686-693; Scovassi *et al.* (1986) *Eur. J. Biochem.* 159:77-84; Simonin *et al.* (1991) *Anal. Biochem.* 195:226-231; Masutani *et al.* (1994) *Eur. J. Biochem.* 220:607-614; herein incorporated by reference.

It is recognized that the plant cell can be transformed with a nucleotide sequence encoding PARP, a nucleotide sequence encoding a portion of PARP, preferably the C-terminal portion of PARP, as well as with a nucleotide sequence

encoding the antisense sequence for the PARP gene, or portions thereof. In this manner, the level of expression of the PARP in the plant cell can be modulated, i.e., increased or decreased, respectively. Levels of expression of the sense or antisense sequence can be regulated by the promoter utilized to express the gene.

5 Promoters for the expression of genes in plant cells are known in the art. Promoters are available for constitutive, tissue specific, inducible, etc. Such promoters include, for example, 35S promoter, Meyer *et al.* (1997) *J. Gen. Virol.* 78:3147-3151; biotin carboxylase, Bas *et al.* (1997) *Plant Mol. Biol.* 35:539-550; oxidase, Lasserre *et al.* (1997) *Mol. Gen. Genet.* 256:211-222; cab, Shiina *et al.* (1997) 10 *Plant Physiol.* 115:477-483; phospholipase, Xu *et al.* (1997) *Plant Physiol.* 115:387-395; farnesyltransferase, Zhou *et al.* (1997) *Plant J.* 12:921-930; plastocyanin, Helliwell *et al.* (1997) *Plant J.* 12:499-506; CVMV promoter, Verdaquer *et al.* (1996) *Plant Mol. Biol.* 31:1129-1139; actin, An *et al.* (1996) *Plant J.* 10:107-121; heat shock, Prandl *et al.* (1996) *Plant Mol. Biol.* 31:157-162; ubiquitin, thionin, 35S, 15 Holtorf *et al.* (1995) *Plant Mol. Biol.* 29:637-646; Callis *et al.* (1990) *J. Biol. Chem.* 265:12486-12493; histone, Atanossova *et al.* (1992) *Plant J.* 2:291-300; rol C, Fladung *et al.* (1993) *Plant Mol. Biol.* 23:749-757; histone, Brignon *et al.* (1993) *Plant J.* 4:445-457; Lepetit *et al.* (1992) *Mol. Gen. Genet.* 231:276-285.

As indicated, recent studies on the mechanism of PARP suggests involvement 20 of the enzyme in regulation of DNA repair, recombination and replication. The enzyme is rapidly activated by DNA and exhibits a high affinity for naked single-stranded or double-stranded DNA. Any perturbation in the cellular morphology and/or physiology that causes a change in chromatin conformation generally results in a rapid increase in PARP activity. PARP is an important modulator of the fate of 25 DNA introduced into a plant cell. Accordingly, plants transformed with either a sense or antisense PARP nucleotide sequence may be utilized to increase transformation frequency in plant cells. Therefore, the present invention provides for the regulation of the levels of PARP in the plant cell to determine its effect on plant transformation and gene targeting.

It is further recognized that because the enzyme plays a role in cellular stress, it may be beneficial to increase the levels of the enzyme to prevent plant disease or pathogen attack. In this manner, constitutive or inducible promoters may be utilized.

Constitutive promoters include, for example, those disclosed in U.S. Patent Nos.

5 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; 5,608,142, herein incorporated by reference. Inducible promoters are known in the art and include, for example, pathogen inducible promoters, such as promoters from pathogenesis-related proteins (PR proteins) which are induced following infection by a pathogen; *e.g.*, PR proteins, SAR proteins, beta-1,3-glucanase, chitinase, etc. See,
10 for example, Redolfi *et al.* (1983) *Neth. J. Plant Pathol.* 89:245-254; Uknes *et al.* (1992) *The Plant Cell* 4:645-656; and Van Loon (1985) *Plant Mol. Virol.* 4:111-116. Of interest are promoters that are expressed locally at or near the site of pathogen infection. See, for example, Marineau *et al.* (1987) *Plant Mol. Biol.* 9:335-342; Matton *et al.* (1989) *Molecular Plant-Microbe Interactions* 2:325-331; Somsisch *et al.*
15 *al.* (1986) *Proc. Natl. Acad. Sci. USA* 83:2427-2430; Somsisch *et al.* (1988) *Molecular and General Genetics* 2:93-98; and Yang, Y (1996) *Proc. Natl. Acad. Sci. USA* 93:14972-14977. See also, Chen *et al.* (1996) *Plant J.* 10:955-966; Zhang *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:2507-2511; Warner *et al.* (1993) *Plant J.* 3:191-201; Siebertz *et al.* (1989) *Plant Cell* 1:961-968; and the references cited therein. Of
20 particular interest is the inducible promoter for the maize PRms gene, whose expression is induced by the pathogen *Fusarium moniliforme* (see, for example, Cordero *et al.* (1992) *Physiological and Molecular Plant Pathology* 41:189-200).

The PARP genes or antisense nucleotides of the invention can be introduced into any plant. The genes or nucleotide sequences to be introduced will be used in
25 expression cassettes for expression in any plant of interest.

Such expression cassettes will comprise a transcriptional initiation region linked to the gene encoding the PARP gene or antisense nucleotide of interest. Such an expression cassette is provided with a plurality of restriction sites for insertion of the gene of interest to be under the transcriptional regulation of the regulatory regions.

30 The expression cassette may additionally contain selectable marker genes.

The transcriptional initiation region, the promoter, may be native or analogous or foreign or heterologous to the plant host. Additionally, the promoter may be the natural sequence or alternatively a synthetic sequence. By foreign is intended that the transcriptional initiation region is not found in the native plant into which the
5 transcriptional initiation region is introduced. As used herein a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.

The transcriptional cassette will include in the 5'-3' direction of transcription, a transcriptional and translational initiation region, a DNA sequence of interest, and a
10 transcriptional and translational termination region functional in plants. The termination region may be native with the transcriptional initiation region, may be native with the DNA sequence of interest, or may be derived from another source. Convenient termination regions are available from the Ti-plasmid of *A. tumefaciens*, such as the octopine synthase and nopaline synthase termination regions. See also,
15 Guerineau *et al.* (1991) *Mol. Gen. Genet.* 262:141-144; Proudfoot (1991) *Cell* 64:671-674; Sanfacon *et al.* (1991) *Genes Dev.* 5:141-149; Mogen *et al.* (1990) *Plant Cell* 2:1261-1272; Munroe *et al.* (1990) *Gene* 91:151-158; Ballas *et al.* (1989) *Nucleic Acids Res.* 17:7891-7903; Joshi *et al.* (1987) *Nucleic Acid Res.* 15:9627-9639.

The genes of the invention are provided in expression cassettes for expression
20 in the plant of interest. The cassette will include 5' and 3' regulatory sequences operably linked to the gene of interest. The cassette may additionally contain at least one additional gene to be cotransformed into the organism. Alternatively, the additional gene(s) can be provided on another expression cassette. Where appropriate, the gene(s) may be optimized for increased expression in the transformed plant. That
25 is, the genes can be synthesized using plant preferred codons for improved expression. Methods are available in the art for synthesizing plant preferred genes. See, for example, U.S. Patent Nos. 5,380,831, 5,436, 391, and Murray *et al.* (1989) *Nucleic Acids Res.* 17:477-498, herein incorporated by reference.

Additional sequence modifications are known to enhance gene expression in a
30 cellular host. These include elimination of sequences encoding spurious

polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences which may be deleterious to gene expression.

The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell.

- 5 When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.

The expression cassettes may additionally contain 5' leader sequences in the expression cassette construct. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include: picornavirus leaders, for
10 example, EMCV leader (Encephalomyocarditis 5' noncoding region) (Elroy-Stein *et al.* (1989) *PNAS USA* 86:6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (Allison *et al.* (1986); MDMV leader (Maize Dwarf Mosaic Virus); *Virology* 154:9-20), and human immunoglobulin heavy-chain binding protein (BiP), (Macejak *et al.* (1991) *Nature* 353:90-94; untranslated leader from the coat
15 protein mRNA of alfalfa mosaic virus (AMV RNA 4), (Jobling *et al.* (1987) *Nature* 325:622-625; tobacco mosaic virus leader (TMV), (Gallie, D.R. *et al.* (1989) *Molecular Biology of RNA*, pages 237-256; and maize chlorotic mottle virus leader (MCMV) (Lommel, S.A. *et al.* (1991) *Virology* 81:382-385). See also, Della-Cioppa *et al.* (1987) *Plant Physiology* 84:965-968. Other methods known to enhance
20 translation can also be utilized, for example, introns, and the like.

In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Towards this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to
25 provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, *in vitro* mutagenesis, primer repair, restriction, annealing, resubstitutions, *e.g.* transitions and transversions, may be involved.

The genes of the present invention can be used to transform any plant. In this
30 manner, genetically modified plants, plant cells, plant tissue, seed, and the like can be

obtained. Transformation protocols may vary depending on the type of plant or plant cell, *i.e.* monocot or dicot, targeted for transformation. Suitable methods of transforming plant cells include microinjection (Crossway *et al.* (1986) *Biotechniques* 4:320-334), electroporation (Riggs *et al.* (1986) *Proc. Natl. Acad. Sci. USA* 83:5602-5606, *Agrobacterium* mediated transformation (Hinchey *et al.* (1988) *Biotechnology* 6:915-921), direct gene transfer (Paszkowski *et al.* (1984) *EMBO J.* 3:2717-2722), and ballistic particle acceleration (see, for example, Sanford *et al.*, U.S. Patent 4,945,050; Tomes *et al.* Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment In Gamborg and Phillips (eds.) *Plant Cell, Tissue and Organ Culture: Fundamental Methods*, Springer-Verlag, Berlin (1995); and McCabe *et al.* (1988) *Biotechnology* 6:923-926). Also see, Weissinger *et al.* (1988) *Ann. Rev. Genet.* 22:421-477; Sanford *et al.* (1987) *Particulate Science and Technology* 5:27-37 (onion); Christou *et al.* (1988) *Plant Physiol.* 87:671-674 (soybean); McCabe *et al.* (1988) *Bio/Technology* 6:923-926 (soybean); Datta *et al.* (1990) *Biotechnology* 8:736-740 (rice); Klein *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:4305-4309 (maize); Klein *et al.* (1988) *Biotechnology* 6:559-563 (maize); Tomes *et al.* Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment in Gamborg and Phillips (eds.) *Plant Cell, Tissue and Organ Culture: Fundamental Methods*, Springer-Verlag, Berlin (1995) (maize); Klein *et al.* (1988) *Plant Physiol.* 91:440-444 (maize); Fromm *et al.* (1990) *Biotechnology* 8:833-839 (maize); Hooydaas-Van Slogteren & Hooykaas (1984) *Nature (London)* 311:763-764; Bytebier *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:5345-5349 (Liliaceae); De Wet *et al.* (1985) in *The Experimental Manipulation of Ovule Tissues* ed. G.P. Chapman *et al.*, pp. 197-209. Longman, NY (pollen); Kaeppler *et al.* (1990) *Plant Cell Reports* 9:415-418; and Kaeppler *et al.* (1992) *Theor. Appl. Genet.* 84:560-566 (whisker-mediated transformation); D Halluin *et al.* (1992) *Plant Cell* 4:1495-1505 (electroporation); Li *et al.* (1993) *Plant Cell Reports* 12:250-255 and Christou and Ford (1995) *Annals of Botany* 75:407-413 (rice); Osjoda *et al.* (1996) *Nature Biotechnology* 14:745-750 (maize via *Agrobacterium tumefaciens*); all of which are herein incorporated by reference.

The cells which have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick *et al.* (1986) *Plant Cell Reports* 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that the subject phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure the desired phenotype or other property has been achieved.

The present invention also provides isolated nucleic acid comprising polynucleotides of sufficient length and complementarity to a gene to use as probes or amplification primers in the detection, quantitation, or isolation of gene transcripts. For example, isolated nucleic acids of the present invention can be used as probes in detecting deficiencies in the level of mRNA in screenings for desired transgenic plants, for detecting mutations in the gene (e.g., substitutions, deletions, or additions), for monitoring upregulation of expression or changes in enzyme activity in screening assays of compounds, for detection of any number of allelic variants (polymorphisms) of the gene, or for use as molecular markers in plant breeding programs. The isolated nucleic acids of the present invention can also be employed for use in sense or antisense suppression of a PARP gene in a host cell, tissue, or plant. See, *Tools to Determine the Function of Genes*, 1995 Proceedings of the Fiftieth Annual Corn and Sorghum Industry Research Conference, American Seed Trade Association, Washington, D.C., 1995. Additionally, non-translated 5' or 3' regions of the polynucleotides of the present invention can be used to modulate turnover of heterologous mRNAs and/or protein synthesis.

The present invention provides a method of genotyping a plant comprising a polynucleotide of the present invention. Preferably, the plant is a monocot, such as maize or sorghum. Genotyping provides a means of distinguishing homologs of a chromosome pair and can be used to differentiate segregants in a plant population. Molecular marker methods can be used for phylogenetic studies, characterizing genetic relationships among crop varieties, identifying crosses or somatic hybrids,

localizing chromosomal segments affecting monogenic traits, map based cloning, and the study of quantitative inheritance. See, e.g., *Plant Molecular Biology: A Laboratory Manual*, Chapter 7, Clark, Ed., Springer-Verlag, Berlin (1997). For molecular marker methods, see generally, *The DNA Revolution* by Andrew H.

- 5 Paterson 1996 (Chapter 2) in: *Genome Mapping in Plants* (ed. Andrew H. Paterson) by Academic Press/R. G. Landis Company, Austin, Texas, pp.7-21.

The particular method of genotyping in the present invention may employ any number of molecular marker analytic techniques such as, but not limited to, restriction fragment length polymorphisms (RFLPs). RFLPs are the product of allelic
10 differences between DNA restriction fragments caused by nucleotide sequence variability. As is well known to those of skill in the art, RFLPs are typically detected by extraction of genomic DNA and digestion with a restriction enzyme. Generally, the resulting fragments are separated according to size and hybridized with a probe; single copy probes are preferred. Restriction fragments from homologous
15 chromosomes are revealed. Differences in fragment size among alleles represent an RFLP. Thus, the present invention further provides a means to follow segregation of a PARP gene or nucleic acid of the present invention as well as chromosomal sequences genetically linked to these genes or nucleic acids using such techniques as RFLP analysis. Linked chromosomal sequences are within 50 centiMorgans (cM),
20 often within 40 or 30 cM, preferably within 20 or 10 cM, more preferably within 5, 3, 2, or 1 cM of a PARP gene.

In the present invention, the nucleic acid probes employed for molecular marker mapping of plant nuclear genomes selectively hybridize, under selective hybridization conditions, to a gene encoding a polynucleotide of the present invention.
25 In preferred embodiments, the probes are selected from polynucleotides of the present invention. Typically, these probes are cDNA probes or *Pst I* genomic clones. The length of the probes is discussed in greater detail, *supra*, but are typically at least 15 bases in length, more preferably at least 20, 25, 30, 35, 40, or 50 bases in length. Generally, however, the probes are less than about 1 kilobase in length. Preferably,
30 the probes are single copy probes that hybridize to a unique locus in a haploid

chromosome complement.

The method of detecting an RFLP comprises the steps of (a) digesting genomic DNA of a plant with a restriction enzyme; (b) hybridizing a nucleic acid probe, under selective hybridization conditions, to a sequence of a polynucleotide of the present of said genomic DNA; (c) detecting therefrom a RFLP. Other methods of differentiating polymorphic (allelic) variants of polynucleotides of the present invention can be had by utilizing molecular marker techniques well known to those of skill in the art including such techniques as: 1) single stranded conformation analysis (SSCP); 2) denaturing gradient gel electrophoresis (DGGE); 3) RNase protection assays; 4) allele-specific oligonucleotides (ASOs); 5) the use of proteins which recognize nucleotide mismatches, such as the *E. coli* mutS protein; and 6) allele-specific PCR. Other approaches based on the detection of mismatches between the two complementary DNA strands include clamped denaturing gel electrophoresis (CDGE); heteroduplex analysis (HA); and chemical mismatch cleavage (CMC).

Thus, the present invention further provides a method of genotyping comprising the steps of contacting, under stringent hybridization conditions, a sample suspected of comprising a polynucleotide of the present invention with a nucleic acid probe. Generally, the sample is a plant sample; preferably, a sample suspected of comprising a maize polynucleotide of the present invention (e.g., gene, mRNA). The nucleic acid probe selectively hybridizes, under stringent conditions, to a subsequence of a polynucleotide of the present invention comprising a polymorphic marker. Selective hybridization of the nucleic acid probe to the polymorphic marker nucleic acid sequence yields a hybridization complex. Detection of the hybridization complex indicates the presence of that polymorphic marker in the sample. In preferred embodiments, the nucleic acid probe comprises a polynucleotide of the present invention.

EXPERIMENTAL

Materials and Methods

Chemicals and Reagents

5 All chemicals used in this study were of molecular biology grade. Trizma
base (Tris (hydroxymethyl) aminomethane; abbreviated hereafter as Tris), N-2
hydroxy-ethyl-pipercazine-N'-2-ethane sulfonic acid (Hepes),
Ethylenediaminetetraacetic acid, sodium salt (EDTA), Magnesium chloride, Urea,
were procured from Sigma Chemical Co. Analytical grade glycerol was obtained
10 from Baxter. Dithiothreitol (DTT), PefablocSC, Pepstatin, Bestatin, all restriction
enzymes, DNA and RNA purification kits as well as markers were purchased from
Boehringer Mannheim. Immunodetection kits for Western blots, silver staining and
Colloidal Coomassie Blue staining were from Novex. All radioactive chemicals were
purchased from NEN-Dupont and NEN. Chromatographic resins were purchased
15 either from Sigma, BioRad or Pharmacia.

Cell Culture

The enzyme is isolated from a Hi II embryogenic callus cell line.
Exponentially growing cultures of 612B4 cells were maintained in dark at 28°C.
20 (Armstrong *et al.* (1992) *Theor. Appl. Genet.* 84:755-762). The cell suspensions are
in MS medium supplemented with 2-4-dichlorophenoxyacetic acid (2.5 mg/l).
Cultures are grown for a week on a gyratory shaker at 150 rpm and harvested by
decantation. Routinely, 60-80 g of cells are obtained from 800-900 ml cultures grown
in 12-14 flasks.

25 Cells are harvested by filtration and used to prepare whole cell extracts (WCE)
from 612B4 cells using the Bionebulizer (Glas-Col, Terre Haute, Indiana). The
process for WCE preparation is outlined in Schema 1. All operations were carried out
at 4°C or on ice unless mentioned otherwise.

Chromatography on Heparin-agarose: About 300 ml of Heparin -agarose
30 (Sigma) was washed extensively with 20 mM Hepes-KOH pH 7.9, 0.1 mM EDTA,

20% glycerol (HGED buffer), packed into a 5.0 x 30 cm Econo column (Biorad) and connected to the Econo System (Biorad). The matrix was equilibrated with HGED + 100 mM KCl. Three batches of crude WCE extract (approx. 1.8-2.0 g of total pooled protein in 60-80 ml) were loaded on the column at a flow rate of 15-20 ml/hr. The column was washed extensively with equilibration buffer till the A_{280} of the effluent was < 0.1 unit (approx. 900 ml).

Small aliquots of peak fractions were saved for PARP assays and all fractions (7-8 ml each) showing $A_{280} > 0.1$ unit were pooled. Protein was precipitated by adding solid ammonium sulfate (0.4 g/ml). The mixture was centrifuged at 40,000 x g for 30 min., dissolved in minimum amount HGED and dialyzed against HGED+100 mM KCl containing Pefabloc and DTT. This fraction is designated HA-1. The column was further washed with 900 ml each HGED + 400 mM KCl followed by HGED + 1 M KCl. Fractions from both washes were processed as above and designated as HA-2 and HA-3. PARP assays were performed on HA-1, 2 and 3 and the active fraction (HA-2) was used for further purification.

Chromatography on DNA-cellulose: DNA-cellulose (Sigma) was washed extensively with HGED and packed in the Econo column (2.5 x 30 cm). The column was connected to the Econo System and equilibrated with HGED+100mM KCl. Partially pure PARP from three Heparin-agarose column was loaded on the DNA-cellulose column. Unbound protein was removed by washing with HGED + 100 mM KCl (200 ml; designated as DC-1). The bound protein was eluted with HGED + 1M KCl (designated DC-2). All fractions was processed as described above for activity and protein.

Chromatography on Histone-agarose: Histone-agarose (Sigma) was washed extensively with HGED and packed into an Econo column (1.5 x 15 cm). The column was equilibrated in HGED + 100 mM KCl. Active fraction from DNA-cellulose (DC-2) was further fractionated on Histone-agarose by washing the column successively with HGED containing 100 mM, 400 mM and 1 M KCl. All fractions were processed

as above and dialyzed against 20 mM Tris-HCl buffer pH 7.9 containing 100 mM KCl.

Chromatography on Mini-Q column: Mini-Q column (Pharmacia) was
5 connected to Smart-LC (Pharmacia) and equilibrated by washing with five bed
volumes of HGED followed by five bed volumes of Tris-HCl buffer + 100 mM KCl.
Active PARP from the Histone-agarose step was loaded on the column. The column
was washed with three bed volumes of equilibration buffer and 400 µl fractions were
collected. Column was further developed using a step gradient of KCl at 400 mM,
10 600 mM and 1M in Tris-HCl, pH 8.0. All fractions were tested for PARP activity as
described below.

Enzyme Assays

Catalytic activity of PARP is assayed following published protocols (Shah *et al.* (1995) *Anal. Biochem* 227:1-13) with modifications suitable for the plant enzyme.
15 Briefly, the enzyme (in a total volume of 25 µl of 20 mM Hepes pH 7.9, 100 mM
KCl) is incubated with 2.5-5 µCi of ∞ -³²P-NAD⁺, 2 µl/ml final concentration of
bovine histone (fraction IV), 2 µg of activated calf thymus DNA and 0.5 mM DTT.
The reactions are carried out at 6°C unless otherwise mentioned. At the end of the
appropriate time intervals, the labeled protein is precipitated with 25% TCA. The
20 precipitate is collected by centrifugation at 16,000 x g for 10 min., washed 2 x with
5% TCA and counted in a LSC. Protein heated at 65°C for 5 min. is used as a
negative control.

Microsequencing

25 Protein samples obtained from the Mini-Q column purification step was
electrophoresed in duplicate on a 10% polyacrylamide gels using 0.1% SDS in the
running buffer (Shah *et al.* (1995) *Anal. Biochem* 227:1-13). One half of the gel was
used to detect protein bands with a Colloidal Coomassie staining kit (Novex)
following manufacturer s instructions. The other half was used in the activity blot
30 assay to confirm position of the active PARP on the gel. Stained protein band

corresponding to active PARP was cut out from the gel and used microsequencing carried out at the W.M. Keck Foundation Biotechnology Resource Laboratory if Yale University. *In gel* tryptic digestion of the protein, Matrix Assisted Laser Desorption Mass Spectrometry (MALDI-MS) of the isolated peptides, and amino sequencing of representative peptides was carried out following protocols detailed elsewhere (Stone *et al.* (1990) *In: Methods in Enzymology* 193:389-412); (Stone *et al.* (1991) *In: Methods in Protein Sequence Analysis* 133-141); Williams *et al.* (1995) *In: Techniques in Protein Chemistry* 6:143-152); Williams *et al.* (1995) *In: Protein Protocol Handbook* 365-378).

Antipeptide Antibodies

Synthesis of the peptide antigens and antibody generation was carried out at Research Genetics, Inc. Two peptides (P-1 and P-2) were used as for antibody generation using two different protocols. In the first protocol, peptide P-1 was synthesized as a multiple antigenic peptide (MAP) following published protocols (Tam, J.P. (1988) *Proc. Nat. Acad. Sci. USA* 85:5409-5413). Antiserum was collected and analyzed for cross-reactivity to PARP using Western blots (Shah *et al.* (1995) *Anal. Biochem* 227:1-13). In the second protocol, P-2 was synthesized as MAP (Tam, J.P. (1988) *Proc. Natl. Acad. Sci. USA* 85:5409-5413) as well as a linear peptide (Barany *et al.* (1980) *In: The Peptides* 2:1-284). The linear peptide was conjugated to hemocyanin using published methods (Walter *et al.* (1980) *Proc. Natl. Acad. Sci. USA* 77:5197-5200) and used for immunization. The immunization protocol for both types of antigens was essentially the same and is detailed below.

Two New Zealand rabbits (4-6 months old) were used for immunization with each type of antigen. The antigens were prepared by dissolving 500 µg MAP peptide in 500 µl of saline and mixed with equal 500 µl of complete Freund's adjuvant and injected subcutaneously at three to four dorsal sites. Same concentration of each antigen (in saline) was mixed with equal volume of incomplete Freund's adjuvant and injected as before at two, four and six weeks after the first immunization. Animals were bled from the auricular artery to collect 30-50 ml blood on days 0, 27, 57 and 69.

Blood samples were allowed to clot at room temperature for 15 min. and serum was isolated from each sample by centrifugation at 5,000 x g for 10 min. Cell-free serum was decanted gently into a clean tube and stored at -20°C till further use.

5 **cDNA Cloning**

 Total RNA was isolated from corn tissues with TRIzol Reagent (Life Technology, Inc. Gaithersburg, MD) using a modification of the guanidine isothiocyanate/acid-phenol procedure described by Chomczynski and Sacchi (Chomczynski *et al.* (1987) *Anal. Biochem* 162:156). In brief, plant tissue samples
10 were pulverized in liquid nitrogen before the addition of the TRIzol Reagent, and then were further homogenized with a mortar and pestle. Addition of chloroform by centrifugation was conducted for separation of an aqueous phase and an organic phase. The total RNA was recovered by precipitation with isopropyl alcohol from the aqueous phase.

15 The selection of poly(A) + RNA from total RNA was performed using PolyA Tract system (Promega Corporation, Madison, WI). In brief, biotinylated oligo (dT) primers were used to hybridize to the 3' poly(A) tails on mRNA. The hybrids were captured using streptavidin coupled to paramagnetic particles and a magnetic separation stand. The mRNA was washed at high stringent condition and eluted by
20 RNase-free deionized water.

 Synthesis of the cDNA was performed and unidirectional cDNA libraries were constructed using the SuperScript Plasmid System (Life Technology, Inc., Gaithersburg, MD). First strand of cDNA was synthesized by priming an oligo(dT) primer containing a Not I site. The reaction was catalyzed by SuperScript Reverse
25 Transcriptase II at 45°C. The second strand of cDNA was labeled with alpha-³²P-dCTP and portions of the molecules smaller than 500 base pairs and unligated adapters were removed by Sephacryl-S400 chromatography. The selected cDNA molecules were ligated into pSPORT1 reference vector between the Not I and Sal I sites.

Individual colonies were picked and DNA was prepared either by PCR with M13 forward primers and M13 reverse primers, or by plasmid miniprep isolation. All the cDNA clones were sequenced using M13 reverse primers.

5 **Analytical**

Protein was estimated by the Bradford method (Bradford, M. (1976) *ibid* 72:248-254) using bovine γ -globulin as standard. Activity blots, Western blots and product analysis were performed essentially following published protocols (10, 20-22), except that all essays were carried out at 6°C.

10

Identification of Zinc Fingers

Two PCR primers were designed to encompass both the Zinc fingers of the maize PARP sequence. These primers were used for reverse transcriptase assisted PCR using the Titan 1 tube RT-PCR kit from Boeheringer Mannheim. Maize callus and leaf mRNA was used as template. The PCR product was purified using Qia Quick PCR product purification columns (Qiagen) and sequenced using an ABI sequencer. Sequenced data is shown in SEQ ID NO. 5.

15

Isolation of PARP from maize cells

20

Cells



(60-80 g)



Suspend in Nebulization Buffer (4 ml/g)

25



(20 mM Hepes pH 7.9, 20% glycerol, 0.4 molal sorbitol, 0.1 mM EDTA)
(+DTT and PI cocktail)



30

Bionebulization at 100 psi x 4



Filter through cheesecloth




Filtrate



35

Add 0.1 volume of SASS

-25-



Scheme I

II publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

THAT WHICH IS CLAIMED:

- 1 ✓ 1. An isolated DNA molecule comprising a nucleotide sequence selected
2 from the group consisting of:
3
4 a) a sequence encoding a poly ADP-ribose polymerase having the amino acid
5 sequence set forth in SEQ ID NO. 2,
6 b) the nucleotide sequence set forth in SEQ ID NO. 1,
7 c) a nucleotide sequence that corresponds to an antisense sequence for the
8 nucleotide sequence set forth in SEQ ID NO. 1,
9 d) a nucleotide sequence encoding the C-terminal domain of a poly ADP-
10 ribose polymerase having the amino acid sequence set forth in SEQ ID
11 NO. 2,
12 e) a nucleotide sequence encoding the C-terminal domain of a poly ADP-
13 ribose polymerase having the amino acid sequence set forth in SEQ ID
14 NO. 4,
15 f) the nucleotide sequence set forth in SEQ ID NO. 3,
16 g) a nucleotide sequence that hybridizes to any one of the nucleotide
17 sequence of a) - f) under stringent conditions.
1 2. A chimeric gene comprising a promoter capable of driving expression of a
2 gene in a plant cell operably linked to a nucleotide sequence of claim 1.
1 3. The chimeric gene of claim 2, wherein the nucleotide sequence encodes a
2 poly ADP-ribose polymerase having the amino acid sequence set forth in SEQ ID NO.
3 2.
1 4. The chimeric gene of claim 3, wherein said coding sequence is the
2 nucleotide sequence set forth in SEQ ID NO. 1.
1 5. A vector comprising the chimeric gene of claim 4.
1 6. A plant cell transformed with the chimeric gene of claim 5.
1 7. A plant comprising the chimeric gene of claim 4.

1 8. The chimeric gene of claim 2, wherein the nucleotide sequence is an
2 antisense sequence for a plant poly ADP-ribose polymerase.

1 9. A vector comprising the chimeric gene of claim 8.

1 10. A plant cell transformed with the vector of claim 9.

1 11. A plant comprising the chimeric gene of claim 8.

1 / 12. A transformed plant having incorporated into its genome a DNA molecule,
2 said molecule comprising a promoter capable of driving expression of a gene in a
3 plant cell operably linked to a nucleotide sequence selected from the group consisting
4 of:

6 a) a sequence encoding a poly ADP-ribose polymerase having the amino acid
7 sequence set forth in SEQ ID NO. 2,

8 b) the nucleotide sequence set forth in SEQ ID NO. 1,

9 c) a nucleotide sequence that corresponds to an antisense sequence for the
10 nucleotide sequence set forth in SEQ ID NO. 1,

11 d) a nucleotide sequence encoding the C-terminal domain of a poly ADP-
12 ribose polymerase having the amino acid sequence set forth in SEQ ID
13 NO. 2,

14 e) a nucleotide sequence encoding the C-terminal domain of a poly ADP-
15 ribose polymerase having the amino acid sequence set forth in SEQ ID
16 NO. 4,

17 f) the nucleotide sequence set forth in SEQ ID NO. 3,

18 g) a nucleotide sequence that hybridizes to the nucleotide sequence of a) - f)
19 under stringent conditions.

1 13. The transformed plant of claim 12, wherein the nucleotide sequence
2 encodes a poly ADP-ribose polymerase having the amino acid sequence set forth in
3 SEQ ID NO. 2.

1 14. The transformed plant of claim 13, wherein said coding sequence is the
2 nucleotide sequence set forth in SEQ ID NO. 1.

1 15. The transformed plant of claim 12, wherein the nucleotide sequence is an
2 antisense sequence for a plant poly ADP-ribose polymerase.

1 16. The transformed plant of claim 12, wherein said coding sequence encodes
2 a plant poly ADP-ribose polymerase having the amino acid sequence set forth in SEQ
3 ID NO. 2.

1 17. The transformed plant of claim 12, wherein said plant is a dicot.

1 18. The transformed plant of claim 13, wherein said plant is a monocot.

1 19. The transformed plant of claim 18, wherein said plant is maize.

1 20. Seed of the plant of any one of claims 17-19.

1 ✓ 21. A method for modulating the metabolic state of a plant cell, said method
2 comprising transforming said plant with a DNA construct, said construct comprising a
3 promoter that drives expression in a plant cell operably linked with a nucleotide
4 sequence selected from the group consisting of:

5 a) a sequence encoding a poly ADP-ribose polymerase having the amino acid
6 sequence set forth in SEQ ID NO. 2,

7 b) the nucleotide sequence set forth in SEQ ID NO. 1,

8 c) a nucleotide sequence that corresponds to an antisense sequence for the
9 nucleotide sequence set forth in SEQ ID NO. 1,

10 d) a nucleotide sequence encoding the C-terminal domain of a poly ADP-
11 ribose polymerase having the amino acid sequence set forth in SEQ ID
12 NO. 2,

13 e) a nucleotide sequence encoding the C-terminal domain of a poly ADP-
14 ribose polymerase having the amino acid sequence set forth in SEQ ID
15 NO. 4,

16 f) the nucleotide sequence set forth in SEQ ID NO. 3,

17 g) a nucleotide sequence that hybridizes to the nucleotide sequence of a) - f)
18 under stringent conditions.

1 22. The method of claim 21, wherein the nucleotide sequence encodes a poly
2 ADP-ribose polymerase having the amino acid sequence set forth in SEQ ID NO. 2.

- 1 23. The method of claim 22, wherein said coding sequence is the nucleotide
- 2 sequence set forth in SEQ ID NO. 1.

POLY ADP-RIBOSE POLYMERASE GENE AND ITS USES

ABSTRACT

Compositions and methods for influencing the metabolic state of plant cells
5 are provided. The compositions comprise poly ADP-ribose polymerase genes and
portions thereof, particularly the maize poly ADP-ribose polymerase gene as well as
antisense nucleotide sequences for poly ADP-ribose polymerase genes. The
nucleotide sequences find use in transforming plant cells to alter the metabolic state of
the transformed plants and plant cells.

RTA01/2058672v1

SEQUENCE LISTING

<110> Mahajan, Pramod B.
Zuo, Zhuang

<120> Poly ADP-Ribose Polymerase Gene and Its Uses

<130> 5718-34, 035718-174234

<140>

<141>

<150> 60/072,785

<151> 1998-01-27

<160> 5

<170> PatentIn Ver. 2.0

<210> 1

<211> 2949

<212> DNA

<213> Zea mays

<220>

<221> CDS

<222> (1)..(2949)

<400> 1

```

atg gcg gcg ccg cca aag gcg tgg aag gcg gag tat gcc aag tct ggg      48
Met Ala Ala Pro Pro Lys Ala Trp Lys Ala Glu Tyr Ala Lys Ser Gly
   1             5             10             15

cgg gcc tcg tgc aag tca tgc cgg tcc cct atc gcc aag gac cag ctc      96
Arg Ala Ser Cys Lys Ser Cys Arg Ser Pro Ile Ala Lys Asp Gln Leu
          20             25             30

cgt ctt ggc aag atg gtt cag gcg tca cag ttc gac ggc ttc atg ccg     144
Arg Leu Gly Lys Met Val Gln Ala Ser Gln Phe Asp Gly Phe Met Pro
          35             40             45

atg tgg aac cat gcc agg tgc atc ttc agc aag aag aac cag ata aaa     192
Met Trp Asn His Ala Arg Cys Ile Phe Ser Lys Lys Asn Gln Ile Lys
          50             55             60

tcc gtt gac gat gtt gaa ggg ata gat gca ctt aga tgg gat gat caa     240
Ser Val Asp Asp Val Glu Gly Ile Asp Ala Leu Arg Trp Asp Asp Gln
          65             70             75             80

```

gag aag ata cga aac tac gtt ggg agt gcc tca gct ggt aca agt tct	288
Glu Lys Ile Arg Asn Tyr Val Gly Ser Ala Ser Ala Gly Thr Ser Ser	
85 90 95	
aca gct gct cct cct gag aaa tgt aca att gag att gct cca tct gcc	336
Thr Ala Ala Pro Pro Glu Lys Cys Thr Ile Glu Ile Ala Pro Ser Ala	
100 105 110	
cgt act tca tgt aga cga tgc agt gaa aag att aca aaa gga tcg gtc	384
Arg Thr Ser Cys Arg Arg Cys Ser Glu Lys Ile Thr Lys Gly Ser Val	
115 120 125	
cgt ctt tca gct aag ctt gag agt gaa ggt ccc aag ggt ata cca tgg	432
Arg Leu Ser Ala Lys Leu Glu Ser Glu Gly Pro Lys Gly Ile Pro Trp	
130 135 140	
tat cat gcc aac tgt ttc ttt gag gta tcc ccg tct gca act gtt gag	480
Tyr His Ala Asn Cys Phe Phe Glu Val Ser Pro Ser Ala Thr Val Glu	
145 150 155 160	
aag ttc tca ggc tgg gat act ttg tcc gat gag gat aag aga acc atg	528
Lys Phe Ser Gly Trp Asp Thr Leu Ser Asp Glu Asp Lys Arg Thr Met	
165 170 175	
ctc gat ctt gtt aaa aaa gat gtt ggc aac aat gaa caa aat aag ggt	576
Leu Asp Leu Val Lys Lys Asp Val Gly Asn Asn Glu Gln Asn Lys Gly	
180 185 190	
tcc aag cgc aag aaa agt gaa aat gat att gat agc tac aaa tcc gcc	624
Ser Lys Arg Lys Lys Ser Glu Asn Asp Ile Asp Ser Tyr Lys Ser Ala	
195 200 205	
agg tta gat gaa agt aca tct gaa ggt aca gtg cga aac aaa ggg caa	672
Arg Leu Asp Glu Ser Thr Ser Glu Gly Thr Val Arg Asn Lys Gly Gln	
210 215 220	
ctt gta gac cca cgt ggt tcc aat act agt tca gct gat atc caa cta	720
Leu Val Asp Pro Arg Gly Ser Asn Thr Ser Ser Ala Asp Ile Gln Leu	
225 230 235 240	
aag ctt aag gag caa agt gac aca ctt tgg aag tta aag gat gga ctt	768
Lys Leu Lys Glu Gln Ser Asp Thr Leu Trp Lys Leu Lys Asp Gly Leu	
245 250 255	
aag act cat gta tcg gct gct gaa tta agg gat atg ctt gag gct aat	816
Lys Thr His Val Ser Ala Ala Glu Leu Arg Asp Met Leu Glu Ala Asn	
260 265 270	

ggg cag gat aca tca gga cca gaa agg cac cta ttg gat cgc tgt gcg	864
Gly Gln Asp Thr Ser Gly Pro Glu Arg His Leu Leu Asp Arg Cys Ala	
275 280 285	
gat gga atg cta ttt gga gcg ctg ggt cct tgc cca gtc tgt gct aat	912
Asp Gly Met Leu Phe Gly Ala Leu Gly Pro Cys Pro Val Cys Ala Asn	
290 295 300	
ggc atg tac tat tat aat ggt cag tac caa tgc agt ggt aat gtg tca	960
Gly Met Tyr Tyr Tyr Asn Gly Gln Tyr Gln Cys Ser Gly Asn Val Ser	
305 310 315 320	
gag tgg tcc aag tgt aca tac tct gcc aca gaa cct gtc cgc gtt aag	1008
Glu Trp Ser Lys Cys Thr Tyr Ser Ala Thr Glu Pro Val Arg Val Lys	
325 330 335	
aag aag tgg caa att cca cat gga aca aag aat gat tac ctt atg aag	1056
Lys Lys Trp Gln Ile Pro His Gly Thr Lys Asn Asp Tyr Leu Met Lys	
340 345 350	
tgg ttc aaa tct caa aag gtt aag aaa cca gag agg gtt ctt cca cca	1104
Trp Phe Lys Ser Gln Lys Val Lys Lys Pro Glu Arg Val Leu Pro Pro	
355 360 365	
atg tca cct gag aaa tct gga agt aaa gca act cag aga aca tca ttg	1152
Met Ser Pro Glu Lys Ser Gly Ser Lys Ala Thr Gln Arg Thr Ser Leu	
370 375 380	
ctg tct tct aaa ggg ttg gat aaa tta agg ttt tct gtt gta gga caa	1200
Leu Ser Ser Lys Gly Leu Asp Lys Leu Arg Phe Ser Val Val Gly Gln	
385 390 395 400	
tca aaa gaa gca gca aat gag tgg att gag aag ctc aaa ctt gct ggt	1248
Ser Lys Glu Ala Ala Asn Glu Trp Ile Glu Lys Leu Lys Leu Ala Gly	
405 410 415	
gcc aac ttc tat gcc agg gtt gtc aaa gat att gat tgt tta att gca	1296
Ala Asn Phe Tyr Ala Arg Val Val Lys Asp Ile Asp Cys Leu Ile Ala	
420 425 430	
tgt ggt gag ctc gac aat gaa aat gct gaa gtc agg aaa gca agg agg	1344
Cys Gly Glu Leu Asp Asn Glu Asn Ala Glu Val Arg Lys Ala Arg Arg	
435 440 445	
ctg aag ata cca att gta agg gag ggt tac att gga gaa tgt gtt aaa	1392
Leu Lys Ile Pro Ile Val Arg Glu Gly Tyr Ile Gly Glu Cys Val Lys	
450 455 460	

aga aca aaa tgc tgc cat ttg att tgt ata aac tgg aat gcc tta gag	1440
Arg Thr Lys Cys Cys His Leu Ile Cys Ile Asn Trp Asn Ala Leu Glu	
465 470 475 480	
tcc tca aaa ggc mgt act gtc act gtt aaa gtt aag ggc cga agt gct	1488
Ser Ser Lys Gly Xaa Thr Val Thr Val Lys Val Lys Gly Arg Ser Ala	
485 490 495	
tgt tca tya agt cct cyg gtt tgc aag aat act gct cac att cct tra	1536
Cys Ser Xaa Ser Pro Xaa Val Cys Lys Asn Thr Ala His Ile Pro Xaa	
500 505 510	
gra tgg gaa aag cat ata caa tgc amc ctt aaa cat gtt ctg acc tgn	1584
Xaa Trp Glu Lys His Ile Gln Cys Xaa Leu Lys His Val Leu Thr Xaa	
515 520 525	
cac nag gtg tgy aca ggc tac tat gta ctc cag atc att gaa cag gat	1632
His Xaa Val Xaa Thr Gly Tyr Tyr Val Leu Gln Ile Ile Glu Gln Asp	
530 535 540	
gat ggg tct gag tgc tac gta ttt cgt aag tgg gga cgg gtt ggg agt	1680
Asp Gly Ser Glu Cys Tyr Val Phe Arg Lys Trp Gly Arg Val Gly Ser	
545 550 555 560	
gag aaa att gga ggg caa aaa ctg gag gag atg tca aaa act gag gca	1728
Glu Lys Ile Gly Gly Gln Lys Leu Glu Glu Met Ser Lys Thr Glu Ala	
565 570 575	
atc aag gaa ttc aaa aga tta ttt ctt gag aag act gga aac tca tgg	1776
Ile Lys Glu Phe Lys Arg Leu Phe Leu Glu Lys Thr Gly Asn Ser Trp	
580 585 590	
gaa gct tgg gaa tgt aaa acc aat ttt cgg aag cag cct ggg aga ttt	1824
Glu Ala Trp Glu Cys Lys Thr Asn Phe Arg Lys Gln Pro Gly Arg Phe	
595 600 605	
tac cca ctt gat gtt gat tat ggt gtt aag aaa gca cca aaa cgg aaa	1872
Tyr Pro Leu Asp Val Asp Tyr Gly Val Lys Lys Ala Pro Lys Arg Lys	
610 615 620	
gat atc agt gaa atg aaa agt tct ctt gct cct caa ttg cta gaa ctc	1920
Asp Ile Ser Glu Met Lys Ser Ser Leu Ala Pro Gln Leu Leu Glu Leu	
625 630 635 640	
atg aag atg ctt ttc aat gtg gag aca tat aga gct gct atg atg gaa	1968
Met Lys Met Leu Phe Asn Val Glu Thr Tyr Arg Ala Ala Met Met Glu	
645 650 655	

ttt gaa awt aat atg tca gaa atg cct ctt ggg aag cta agc mag gra	2016
Phe Glu Xaa Asn Met Ser Glu Met Pro Leu Gly Lys Leu Ser Xaa Xaa	
660 665 670	
aat att gag raa gga ttt gaa gca tta act krg rta cmg rat tta ttt	2064
Asn Ile Glu Xaa Gly Phe Glu Ala Leu Thr Xaa Xaa Xaa Xaa Leu Phe	
675 680 685	
gaa gga cac cgc tna tca agc act ggc ttg ttr gag aaa gct naa ttg	2112
Glu Gly His Arg Xaa Ser Ser Thr Gly Leu Xaa Glu Lys Ala Xaa Leu	
690 695 700	
ttg ytg sga gcm ats syt ttt tca ctc tta tcc ctt cta ttc atc ctc	2160
Leu Xaa Xaa Xaa Xaa Xaa Phe Ser Leu Leu Ser Leu Leu Phe Ile Leu	
705 710 715 720	
ata tta tac ggg atg agg atg att tca tat tca aag gcg aaa atg ctt	2208
Ile Leu Tyr Gly Met Arg Met Ile Ser Tyr Ser Lys Ala Lys Met Leu	
725 730 735	
gaa gct ctg cag gat att gaa att gct tca aag ata gtt ggc ttc gat	2256
Glu Ala Leu Gln Asp Ile Glu Ile Ala Ser Lys Ile Val Gly Phe Asp	
740 745 750	
agc gac agt gat gaa tct ctt gat gat aaa tat atg aaa ctt cac tgt	2304
Ser Asp Ser Asp Glu Ser Leu Asp Asp Lys Tyr Met Lys Leu His Cys	
755 760 765	
gac atc acc ccg ctg gct cac gat agt gaa gat tac aag tta att gag	2352
Asp Ile Thr Pro Leu Ala His Asp Ser Glu Asp Tyr Lys Leu Ile Glu	
770 775 780	
cag tat ctc ctc aac aca cat gct cct act cac aag gac tgg tcg ctg	2400
Gln Tyr Leu Leu Asn Thr His Ala Pro Thr His Lys Asp Trp Ser Leu	
785 790 795 800	
gaa ctg gag gaa gtt ttt tca ctt gat cga gat gga gaa ctt aat aag	2448
Glu Leu Glu Glu Val Phe Ser Leu Asp Arg Asp Gly Glu Leu Asn Lys	
805 810 815	
tac tca aga tat aaa aat aat ctg cat aac aag atg cta tta tgg cac	2496
Tyr Ser Arg Tyr Lys Asn Asn Leu His Asn Lys Met Leu Leu Trp His	
820 825 830	
ggc tca agg ttg acg aat ttt gtg gga att ctt agt caa ggg cta aga	2544
Gly Ser Arg Leu Thr Asn Phe Val Gly Ile Leu Ser Gln Gly Leu Arg	
835 840 845	

att gca cct cct gag gca cct gtt act ggc tat atg ttc ggc aaa ggc 2592
 Ile Ala Pro Pro Glu Ala Pro Val Thr Gly Tyr Met Phe Gly Lys Gly
 850 855 860

ctc tac ttt gca gat cta gta agc aag agc gca caa tac tgt tat gtg 2640
 Leu Tyr Phe Ala Asp Leu Val Ser Lys Ser Ala Gln Tyr Cys Tyr Val
 865 870 875 880

gat agg aat aat cct gta ggt ttg atg ctt ctt tct gag gtt gct tta 2688
 Asp Arg Asn Asn Pro Val Gly Leu Met Leu Leu Ser Glu Val Ala Leu
 885 890 895

gga gac atg tat gaa cta aag aaa gcc acg tcc atg gac aaa cct cca 2736
 Gly Asp Met Tyr Glu Leu Lys Lys Ala Thr Ser Met Asp Lys Pro Pro
 900 905 910

aga ggg aag cat tcg acc aag gga tta ggc aaa acc gtg cca ctg gag 2784
 Arg Gly Lys His Ser Thr Lys Gly Leu Gly Lys Thr Val Pro Leu Glu
 915 920 925

tca gag ttt gtg aag tgg agg gat gat gtc gta gtt ccc tgc ggc aag 2832
 Ser Glu Phe Val Lys Trp Arg Asp Asp Val Val Val Pro Cys Gly Lys
 930 935 940

ccg gtg cca tca tca att agg agc tct gaa ctc atg tac aat gag tac 2880
 Pro Val Pro Ser Ser Ile Arg Ser Ser Glu Leu Met Tyr Asn Glu Tyr
 945 950 955 960

atc gtc tac aac aca tcc cag gtg aag atg cag ttc ttg ctg aag gtg 2928
 Ile Val Tyr Asn Thr Ser Gln Val Lys Met Gln Phe Leu Leu Lys Val
 965 970 975

cgt ttc cat cac aag agg tag 2949
 Arg Phe His His Lys Arg
 980

<210> 2

<211> 982

<212> PRT

<213> Zea mays

<400> 2

Met Ala Ala Pro Pro Lys Ala Trp Lys Ala Glu Tyr Ala Lys Ser Gly
 1 5 10 15

Arg Ala Ser Cys Lys Ser Cys Arg Ser Pro Ile Ala Lys Asp Gln Leu

275		280		285
Asp Gly Met Leu Phe Gly Ala Leu Gly Pro Cys Pro Val Cys Ala Asn				
290		295		300
Gly Met Tyr Tyr Tyr Asn Gly Gln Tyr Gln Cys Ser Gly Asn Val Ser				
305		310		315
				320
Glu Trp Ser Lys Cys Thr Tyr Ser Ala Thr Glu Pro Val Arg Val Lys				
		325		330
				335
Lys Lys Trp Gln Ile Pro His Gly Thr Lys Asn Asp Tyr Leu Met Lys				
		340		345
				350
Trp Phe Lys Ser Gln Lys Val Lys Lys Pro Glu Arg Val Leu Pro Pro				
		355		360
				365
Met Ser Pro Glu Lys Ser Gly Ser Lys Ala Thr Gln Arg Thr Ser Leu				
		370		375
				380
Leu Ser Ser Lys Gly Leu Asp Lys Leu Arg Phe Ser Val Val Gly Gln				
		385		390
				395
				400
Ser Lys Glu Ala Ala Asn Glu Trp Ile Glu Lys Leu Lys Leu Ala Gly				
		405		410
				415
Ala Asn Phe Tyr Ala Arg Val Val Lys Asp Ile Asp Cys Leu Ile Ala				
		420		425
				430
Cys Gly Glu Leu Asp Asn Glu Asn Ala Glu Val Arg Lys Ala Arg Arg				
		435		440
				445
Leu Lys Ile Pro Ile Val Arg Glu Gly Tyr Ile Gly Glu Cys Val Lys				
		450		455
				460
Arg Thr Lys Cys Cys His Leu Ile Cys Ile Asn Trp Asn Ala Leu Glu				
		465		470
				475
				480
Ser Ser Lys Gly Xaa Thr Val Thr Val Lys Val Lys Gly Arg Ser Ala				
		485		490
				495
Cys Ser Xaa Ser Pro Xaa Val Cys Lys Asn Thr Ala His Ile Pro Xaa				
		500		505
				510
Xaa Trp Glu Lys His Ile Gln Cys Xaa Leu Lys His Val Leu Thr Xaa				
		515		520
				525
His Xaa Val Xaa Thr Gly Tyr Tyr Val Leu Gln Ile Ile Glu Gln Asp				

530		535		540	
Asp Gly Ser Glu Cys Tyr Val Phe Arg Lys Trp Gly Arg Val Gly Ser					
545		550		555	560
Glu Lys Ile Gly Gly Gln Lys Leu Glu Glu Met Ser Lys Thr Glu Ala					
	565		570		575
Ile Lys Glu Phe Lys Arg Leu Phe Leu Glu Lys Thr Gly Asn Ser Trp					
	580		585		590
Glu Ala Trp Glu Cys Lys Thr Asn Phe Arg Lys Gln Pro Gly Arg Phe					
	595		600		605
Tyr Pro Leu Asp Val Asp Tyr Gly Val Lys Lys Ala Pro Lys Arg Lys					
	610		615		620
Asp Ile Ser Glu Met Lys Ser Ser Leu Ala Pro Gln Leu Leu Glu Leu					
625		630		635	640
Met Lys Met Leu Phe Asn Val Glu Thr Tyr Arg Ala Ala Met Met Glu					
	645		650		655
Phe Glu Xaa Asn Met Ser Glu Met Pro Leu Gly Lys Leu Ser Xaa Xaa					
	660		665		670
Asn Ile Glu Xaa Gly Phe Glu Ala Leu Thr Xaa Xaa Xaa Xaa Leu Phe					
	675		680		685
Glu Gly His Arg Xaa Ser Ser Thr Gly Leu Xaa Glu Lys Ala Xaa Leu					
	690		695		700
Leu Xaa Xaa Xaa Xaa Xaa Phe Ser Leu Leu Ser Leu Leu Phe Ile Leu					
705		710		715	720
Ile Leu Tyr Gly Met Arg Met Ile Ser Tyr Ser Lys Ala Lys Met Leu					
	725		730		735
Glu Ala Leu Gln Asp Ile Glu Ile Ala Ser Lys Ile Val Gly Phe Asp					
	740		745		750
Ser Asp Ser Asp Glu Ser Leu Asp Asp Lys Tyr Met Lys Leu His Cys					
	755		760		765
Asp Ile Thr Pro Leu Ala His Asp Ser Glu Asp Tyr Lys Leu Ile Glu					
	770		775		780
Gln Tyr Leu Leu Asn Thr His Ala Pro Thr His Lys Asp Trp Ser Leu					

785		790		795		800									
Glu	Leu	Glu	Glu	Val	Phe	Ser	Leu	Asp	Arg	Asp	Gly	Glu	Leu	Asn	Lys
				805					810					815	
Tyr	Ser	Arg	Tyr	Lys	Asn	Asn	Leu	His	Asn	Lys	Met	Leu	Leu	Trp	His
			820					825					830		
Gly	Ser	Arg	Leu	Thr	Asn	Phe	Val	Gly	Ile	Leu	Ser	Gln	Gly	Leu	Arg
		835					840					845			
Ile	Ala	Pro	Pro	Glu	Ala	Pro	Val	Thr	Gly	Tyr	Met	Phe	Gly	Lys	Gly
	850					855					860				
Leu	Tyr	Phe	Ala	Asp	Leu	Val	Ser	Lys	Ser	Ala	Gln	Tyr	Cys	Tyr	Val
865					870					875					880
Asp	Arg	Asn	Asn	Pro	Val	Gly	Leu	Met	Leu	Leu	Ser	Glu	Val	Ala	Leu
				885					890					895	
Gly	Asp	Met	Tyr	Glu	Leu	Lys	Lys	Ala	Thr	Ser	Met	Asp	Lys	Pro	Pro
			900					905					910		
Arg	Gly	Lys	His	Ser	Thr	Lys	Gly	Leu	Gly	Lys	Thr	Val	Pro	Leu	Glu
		915					920					925			
Ser	Glu	Phe	Val	Lys	Trp	Arg	Asp	Asp	Val	Val	Val	Pro	Cys	Gly	Lys
	930					935					940				
Pro	Val	Pro	Ser	Ser	Ile	Arg	Ser	Ser	Glu	Leu	Met	Tyr	Asn	Glu	Tyr
945					950					955				960	
Ile	Val	Tyr	Asn	Thr	Ser	Gln	Val	Lys	Met	Gln	Phe	Leu	Leu	Lys	Val
			965						970					975	
Arg	Phe	His	His	Lys	Arg										
			980												

<210> 3
 <211> 474
 <212> DNA
 <213> Zea mays

<220>
 <221> CDS
 <222> (1)..(474)

```

<400> 3
aac aag atg cta tta tgg cac ggt tca agg ttg acg aat ttt gtg gga 48
Asn Lys Met Leu Leu Trp His Gly Ser Arg Leu Thr Asn Phe Val Gly
  1             5             10             15

att ctt agt caa ggg cta aga att gca cct cct gag gca cct gtt act 96
Ile Leu Ser Gln Gly Leu Arg Ile Ala Pro Pro Glu Ala Pro Val Thr
      20             25             30

ggc tat atg ttc ggc aaa ggc ctc tac ttt gca gat cta gta agc aag 144
Gly Tyr Met Phe Gly Lys Gly Leu Tyr Phe Ala Asp Leu Val Ser Lys
      35             40             45

agc gca caa tac tgt tat gtg gat agg aat aat cct gta ggt ttg atg 192
Ser Ala Gln Tyr Cys Tyr Val Asp Arg Asn Asn Pro Val Gly Leu Met
      50             55             60

ctt ctt tct gag gtt gct tta gga gac atg tat gaa cta aag aaa gcc 240
Leu Leu Ser Glu Val Ala Leu Gly Asp Met Tyr Glu Leu Lys Lys Ala
      65             70             75             80

acg tcc atg gac aaa cct cca aga ggg aag cat tcg acc aag gga tta 288
Thr Ser Met Asp Lys Pro Pro Arg Gly Lys His Ser Thr Lys Gly Leu
      85             90             95

ggc aaa acc gtg cca ctg gag tca gag ttt gtg aag tgg agg gat gat 336
Gly Lys Thr Val Pro Leu Glu Ser Glu Phe Val Lys Trp Arg Asp Asp
      100             105             110

gtc gta gtt ccc tgc ggc aag ccg gtg cca tca tca att agg agc tct 384
Val Val Val Pro Cys Gly Lys Pro Val Pro Ser Ser Ile Arg Ser Ser
      115             120             125

gaa ctc atg tac aat gag tac atc gtc tac aac aca tcc cag gtg aag 432
Glu Leu Met Tyr Asn Glu Tyr Ile Val Tyr Asn Thr Ser Gln Val Lys
      130             135             140

atg cag ttc ttg ctg aag gtg cgt ttc cat cac aag agg tag 474
Met Gln Phe Leu Leu Lys Val Arg Phe His His Lys Arg
      145             150             155

```

```

<210> 4
<211> 157
<212> PRT
<213> Zea mays

```

```

<400> 4

```

Asn Lys Met Leu Leu Trp His Gly Ser Arg Leu Thr Asn Phe Val Gly
 1 5 10 15

Ile Leu Ser Gln Gly Leu Arg Ile Ala Pro Pro Glu Ala Pro Val Thr
 20 25 30

Gly Tyr Met Phe Gly Lys Gly Leu Tyr Phe Ala Asp Leu Val Ser Lys
 35 40 45

Ser Ala Gln Tyr Cys Tyr Val Asp Arg Asn Asn Pro Val Gly Leu Met
 50 55 60

Leu Leu Ser Glu Val Ala Leu Gly Asp Met Tyr Glu Leu Lys Lys Ala
 65 70 75 80

Thr Ser Met Asp Lys Pro Pro Arg Gly Lys His Ser Thr Lys Gly Leu
 85 90 95

Gly Lys Thr Val Pro Leu Glu Ser Glu Phe Val Lys Trp Arg Asp Asp
 100 105 110

Val Val Val Pro Cys Gly Lys Pro Val Pro Ser Ser Ile Arg Ser Ser
 115 120 125

Glu Leu Met Tyr Asn Glu Tyr Ile Val Tyr Asn Thr Ser Gln Val Lys
 130 135 140

Met Gln Phe Leu Leu Lys Val Arg Phe His His Lys Arg
 145 150 155

<210> 5

<211> 530

<212> DNA

<213> Zea mays

<400> 5

ctcgtgcaag tcatgcoggt cccctatcgc caaggaccag ctccgtcttg gcaagatggt 60

tcaggcgtca cagttcgacg gcttcatgcc gatgtggaac catgccaggt gcatcttcag 120

caagaagaac cagataaaat ccgttgacga tgttgaaggg atagatgcac ttagatggga 180

tgatcaagag aagatacgaa actacgttgg gagtgcctca gctggtacaa gttctacagc 240

tgctcctcct gagaaatgta caattgagat tgctccatct gcccgactt catgtagacg 300

atgcagtgaa aagattacaa aaggatcggg ccgtctttca gctaagcttg agagtgaagg 360

tcccaagggg ataccatggg atcatgccaa ctgtttcttt gaggtatccc cgtctgcaac 420

tgttgagaag ttctcaggct gggatacttt gtccgatgag gataagagaa ccatgctcga 480

tcttggttaa aaagatgttg gcaacaatga acaaaataag ggttccaagc 530

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No. 5718-34

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

POLY ADP-RIBOSE POLYMERASE GENE AND ITS USES,

the specification of which

☒ is attached hereto

OR

☐ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

None			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

60/072,785	01/27/1998
Application Number	Filing Date (MM/DD/YYYY)
Application Number	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application (37 C.F.R. § 1.63(d)).

None		
Application No.	Filing Date	Status Patented/Pending/Abandoned
Application. No.	Filing Date	Status Patented/Pending/Abandoned
Application No.	Filing Date	Status Patented/Pending/Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 000826

Direct correspondence to the
attention of and telephone calls to:

W. Murray Spruill
Registration No. 32,943
Tel Raleigh Office (919) 420-2200
Fax Raleigh Office (919) 420-2260

Full name of (first/sole) inventor: Pramod Mahajan

Inventor's

Signature: PBMahajan Date: 1-21-99

Residence: 8029 Brookview Drive, Urbandale, Iowa 50322

Citizenship: India

Post Office Address: same

Full name of second inventor: Zhuang Zuo

Inventor's

Signature: Z Zhuang Date: 1-21-99

Residence: 4728 - 80th Place, Urbandale, Iowa 50322

Citizenship: Peoples Republic of China

Post Office Address: same

RTA01/2059244v1